Stock 6785 ALAR PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Alar Pharmaceuticals Inc.

Equities

6785

TW0006785009

Pharmaceuticals

End-of-day quote Taipei Exchange
Other stock markets
 18:00:00 2024-05-20 EDT 		5-day change 1st Jan Change
270 TWD 0.00% Intraday chart for Alar Pharmaceuticals Inc. +12.27% +28.88%
05-10 Alar Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
03-14 Alar Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2020 2021 2022 2023
Capitalization 1 2,793 2,608 6,555 11,942
Enterprise Value (EV) 1 2,234 2,090 6,071 11,047
P/E ratio -17.1 x -40.6 x -330 x 31.2 x
Yield - - - 0.72%
Capitalization / Revenue 4,655 x - 8,194 x 25.4 x
EV / Revenue 3,723 x - 7,589 x 23.5 x
EV / EBITDA -13.2 x -23 x -137 x 28.5 x
EV / FCF -18.4 x -59.5 x -213 x 35.4 x
FCF Yield -5.43% -1.68% -0.47% 2.82%
Price to Book 4.67 x 4.88 x 12.7 x 13.3 x
Nbr of stocks (in thousands) 57,000 57,000 57,000 57,000
Reference price 2 49.00 45.75 115.0 209.5
Announcement Date 21-04-06 22-03-31 23-03-03 24-03-14
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 0.5 - 0.6 - 0.8 469.3
EBITDA 1 -68.9 -59.09 -168.8 -90.82 -44.16 387.6
EBIT 1 -70.94 -61.39 -170.8 -93.3 -46.53 385.5
Operating Margin -14,188.6% - -28,460.83% - -5,815.88% 82.15%
Earnings before Tax (EBT) 1 -53.77 -67.97 -142.8 -64.23 -32.54 391.1
Net income 1 -53.77 -67.97 -142.8 -64.23 -19.87 382.6
Net margin -10,753.6% - -23,799.5% - -2,483.87% 81.53%
EPS 2 -1.963 -1.942 -2.861 -1.127 -0.3486 6.710
Free Cash Flow 1 -35.15 -56.59 -121.2 -35.15 -28.45 311.7
FCF margin -7,029.68% - -20,203.46% - -3,555.64% 66.42%
FCF Conversion (EBITDA) - - - - - 80.41%
FCF Conversion (Net income) - - - - - 81.46%
Dividend per Share - - - - - 1.500
Announcement Date 20-06-17 20-06-17 21-04-06 22-03-31 23-03-03 24-03-14
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 250 169 559 518 484 895
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -35.1 -56.6 -121 -35.1 -28.4 312
ROE (net income / shareholders' equity) -38.5% -30.2% -36.2% -11.3% -3.79% 54.2%
ROA (Net income/ Total Assets) -30% -16.3% -26.7% -10.2% -5.47% 32.2%
Assets 1 179.4 415.8 535.1 630 363 1,188
Book Value Per Share 2 7.400 5.460 10.50 9.370 9.030 15.70
Cash Flow per Share 2 3.390 1.410 9.840 9.110 7.990 13.00
Capex - 3.95 0.39 1.58 1.14 6.34
Capex / Sales - - 64.17% - 142.37% 1.35%
Announcement Date 20-06-17 20-06-17 21-04-06 22-03-31 23-03-03 24-03-14
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
ALAR PHARMACEUTICALS INC. Stock Alar Pharmaceuticals Inc.
+28.88% 559M
MERCK KGAA Stock Merck KGaA
+14.99% 78.65B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+9.32% 8.94B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-12.05% 5.16B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+53.66% 4.85B
YUHAN CORPORATION Stock Yuhan Corporation
+11.63% 4.19B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-23.67% 2.32B
INDIVIOR PLC Stock Indivior PLC
+12.07% 2.29B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-32.35% 2.19B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+21.04% 2.19B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 6785 Stock
  4. Financials Alar Pharmaceuticals Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW